Mirion Technologies Inc

Mirion Technologies Inc (MIR) Stock Analysis

$14.400

-0.436 (-3.03%)At close

Loading chart…
High
14.980
Open
14.860
VWAP
14.58
Vol
2.50M
Mkt Cap
2.48B
Low
14.350
Amount
36.38M
EV/EBITDA, TTM
18.92

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).

AI analysis of Mirion Technologies Inc (MIR)

sell

Mirion Technologies Inc is not a good buy right now due to its current price of $14.40, which is significantly below analyst price targets ranging from $22 to $27, indicating potential further downside. The RSI is at 28.453, suggesting the stock is oversold, but the recent insider selling and a year-to-date decline of 39.57% raise concerns about future performance. The main risk is the high P/E ratio of 149.73, indicating that the stock may be overvalued relative to its earnings potential.

Valuation Metrics

The current forward P/E ratio for Mirion Technologies Inc (MIR) is 0.00, compared to its 5-year average forward P/E of 26.72.

Forward P/E

Strongly Undervalued
5Y Average P/E
26.72
Current P/E
0.00
Overvalued
34.84
Undervalued
18.61

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
16.47
Current EV/EBITDA
18.92
Overvalued
21.15
Undervalued
11.80

Forward P/S

Fair
5Y Average P/S
2.94
Current P/S
3.01
Overvalued
4.03
Undervalued
1.84

Alphio AI Price Scenarios for MIR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MIR

$21.71

Scenario price

B

Base

Base · 50%MIR

$18.61

Scenario price

B

Bear

Bear · 25%MIR

$14.31

Scenario price

Whales holding MIR

M

Maverick Capital, Ltd.

+ HoldingMIR

+4.67%

3M Return

A

Australian Foundation Investment Company Limited

+ HoldingMIR

+4.57%

3M Return

C

Congress Asset Management Company, LLP

+ HoldingMIR

-2.69%

3M Return

O

Omega Advisors, Inc.

+ HoldingMIR

-7.51%

3M Return

D

Davidson Kempner Capital Management LP

+ HoldingMIR

-18.00%

3M Return

MIR FAQ — answered by Alphio AI

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling). It operates in the Industrials sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Mirion Technologies Inc is not a good buy right now due to its current price of $14.40, which is significantly below analyst price targets ranging from $22 to $27, indicating potential further downside. The RSI is at 28.453, suggesting the stock is oversold, but the recent insider selling and a year-to-date decline of 39.57% raise concerns about future performance. The main risk is the high P/E ratio of 149.73, indicating that the stock may be overvalued relative to its earnings potential.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started